Ankündigung • May 19
Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026 Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026 Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years. Ankündigung • Jan 19
Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026 Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026 Ankündigung • Oct 16
Hindustan Bio Sciences Limited to Report Q2, 2026 Results on Oct 31, 2025 Hindustan Bio Sciences Limited announced that they will report Q2, 2026 results on Oct 31, 2025 Ankündigung • Aug 01
Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025 Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: #31, sagar society, road no. 2, banjara hills, hyderabad - 500 034, hyderabad India New Risk • Aug 01
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.6% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹7.2m revenue, or US$83k). Market cap is less than US$10m (₹94.3m market cap, or US$1.08m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin). Reported Earnings • Aug 01
First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.08 in 1Q 2025) First quarter 2026 results: EPS: ₹0.01 (down from ₹0.08 in 1Q 2025). Revenue: ₹3.35m (down 21% from 1Q 2025). Net income: ₹140.0k (down 83% from 1Q 2025). Profit margin: 4.2% (down from 19% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Ankündigung • Jul 21
Hindustan Bio Sciences Limited to Report Q1, 2026 Results on Jul 31, 2025 Hindustan Bio Sciences Limited announced that they will report Q1, 2026 results on Jul 31, 2025 New Risk • Jun 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹8.1m revenue, or US$94k). Market cap is less than US$10m (₹89.0m market cap, or US$1.03m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change). Reported Earnings • Jun 02
Full year 2025 earnings released: EPS: ₹0.10 (vs ₹0.056 in FY 2024) Full year 2025 results: EPS: ₹0.10 (up from ₹0.056 in FY 2024). Revenue: ₹8.13m (down 23% from FY 2024). Net income: ₹1.01m (up 75% from FY 2024). Profit margin: 12% (up from 5.5% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Ankündigung • May 19
Hindustan Bio Sciences Limited to Report Q4, 2025 Results on May 30, 2025 Hindustan Bio Sciences Limited announced that they will report Q4, 2025 results on May 30, 2025 Ankündigung • Apr 23
Hindustan Bio Sciences Limited Appoints Devanshu Ravinder Dange as Company Secretary and Compliance Officer, Effective April 23, 2025 Hindustan Bio Sciences Limited announced that at the board meeting held on April 23, 2025 the board approved appointment of Mr. Devanshu Ravinder Dange as Company Secretary and Compliance Officer. Reason for Change: Appointed on account of resignation of the previous Company Secretary. Date of appointment is April 23, 2025. Brief Profile: Mr. Devanshu Ravinder Dange is an Associate Member of the Institute of Company Secretaries of India(ICSI). He holds Bachelor's Degree in Commerce from Osmania University. In addition, he is certified in Series XI - Merchant Banking from the National Institute of Securities Markets (NISM). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹8.32, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 77% over the past three years. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₹7.27, the stock trades at a trailing P/E ratio of 51.3x. Average trailing P/E is 46x in the Biotechs industry in India. Total returns to shareholders of 53% over the past three years. Ankündigung • Jan 20
Hindustan Bio Sciences Limited to Report Q3, 2025 Results on Jan 30, 2025 Hindustan Bio Sciences Limited announced that they will report Q3, 2025 results on Jan 30, 2025 New Risk • Jan 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (₹12m revenue, or US$134k). Market cap is less than US$10m (₹104.7m market cap, or US$1.22m). Ankündigung • Dec 31
Hindustan Bio Sciences Limited Announces Resignation of Sukavasi Jyotsna as Company Secretary and Compliance Officer Hindustan Bio Sciences Limited informed that resignation of Mrs. Sukavasi Jyotsna (ACS 68536) for the post of Company Secretary and Compliance Officer has been approved. Date of Resignation: 31 December 2024. Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹11.50, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 171% over the past three years. Ankündigung • Oct 17
Hindustan Bio Sciences Limited to Report Q2, 2025 Results on Oct 30, 2024 Hindustan Bio Sciences Limited announced that they will report Q2, 2025 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹9.61, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 33x in the Biotechs industry in India. Total returns to shareholders of 163% over the past three years. New Risk • Sep 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Revenue is less than US$1m (₹15m revenue, or US$177k). Market cap is less than US$10m (₹94.2m market cap, or US$1.13m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change). Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 155% over the past three years. Ankündigung • Jul 31
Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024 Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time. Location: plot no,31, sagar, society, road no.2, banjarahills, hyderabad-500034, hyderabad India Ankündigung • Jul 22
Hindustan Bio Sciences Limited to Report Q1, 2025 Results on Jul 31, 2024 Hindustan Bio Sciences Limited announced that they will report Q1, 2025 results on Jul 31, 2024 Ankündigung • May 12
Hindustan Bio Sciences Limited to Report Fiscal Year 2024 Results on May 25, 2024 Hindustan Bio Sciences Limited announced that they will report fiscal year 2024 results on May 25, 2024 Ankündigung • Jan 12
Hindustan Bio Sciences Limited to Report Q3, 2024 Results on Jan 31, 2024 Hindustan Bio Sciences Limited announced that they will report Q3, 2024 results on Jan 31, 2024 Ankündigung • Oct 20
Hindustan Bio Sciences Limited to Report Q2, 2024 Results on Oct 31, 2023 Hindustan Bio Sciences Limited announced that they will report Q2, 2024 results on Oct 31, 2023 Ankündigung • Sep 05
Hindustan Bio Sciences Limited Announces Resignation of Goli Seshavataram, Chief Financial Officer Hindustan Bio Sciences Limited announced that Mr. Goli Seshavataram CFO, of the Company has tendered his resignation from the post of the CFO of the Company with effect from August 30, 2023. Ankündigung • Aug 19
Hindustan Bio Sciences Limited Appoints Sukavasi Jyotsna as Company Secretary and Compliance Officer Hindustan Bio Sciences Limited informed that appointment of Mrs. Sukavasi Jyotsna for the post of Company Secretary and Compliance Officer has been approved. Date of Appointment 18th August, 2023. Mrs. Sukavasi Jyotsna is an Associate Member of the Institute of Company Secretaries of India having membership No. ACS 68536. She holds Bachelor Degree in Commerce and having 1 years of experience in the field of Company Secretarial works. Ankündigung • Aug 01
Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023 Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Agenda: To approve the re-appointment of Mr. Venkata Rama Mohan Raju Jampana. Ankündigung • May 19
Hindustan Bio Sciences Limited to Report Q4, 2023 Results on May 30, 2023 Hindustan Bio Sciences Limited announced that they will report Q4, 2023 results on May 30, 2023 Board Change • May 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Non Executive Independent Director Mantena Raju was the last director to join the board, commencing their role in 2010. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 01
Third quarter 2023 earnings released: EPS: ₹0.05 (vs ₹0.002 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹0.05 (up from ₹0.002 loss in 3Q 2022). Revenue: ₹3.18m (up 33% from 3Q 2022). Net income: ₹476.0k (up ₹496.0k from 3Q 2022). Profit margin: 15% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings. Ankündigung • Jan 23
Hindustan Bio Sciences Limited to Report Q3, 2023 Results on Jan 31, 2023 Hindustan Bio Sciences Limited announced that they will report Q3, 2023 results on Jan 31, 2023 Ankündigung • Jan 13
Hindustan Bio Sciences Limited Announces Resignation of Varun Varma Jampana as Non Executive-Non Independent Director Hindustan Bio Sciences Limited announced that Mr. Varun Varma Jampana, Non Executive-Non Independent Director of the company, vide his letter dated 12 January 2023 has tendered his resignation as Non Executive-Non Independent Director of the company with effect from 12 January 2023. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 03
Second quarter 2023 earnings released: ₹0.07 loss per share (vs ₹0.05 loss in 2Q 2022) Second quarter 2023 results: ₹0.07 loss per share (further deteriorated from ₹0.05 loss in 2Q 2022). Net loss: ₹749.0k (loss widened 36% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Ankündigung • Oct 20
Hindustan Bio Sciences Limited to Report Q2, 2023 Results on Oct 31, 2022 Hindustan Bio Sciences Limited announced that they will report Q2, 2023 results on Oct 31, 2022 Ankündigung • Jul 30
Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022 Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022. Ankündigung • Jul 19
Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 29, 2022 Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results at 2:00 PM, Indian Standard Time on Jul 29, 2022 Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 08
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: ₹0.002 loss per share (up from ₹0.11 loss in 3Q 2021). Revenue: ₹2.40m (up ₹2.39m from 3Q 2021). Net loss: ₹20.0k (loss narrowed 98% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings. Reported Earnings • Nov 03
Second quarter 2022 earnings released: ₹0.05 loss per share (vs ₹0.03 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹524.0k (down 84% from 2Q 2021). Net loss: ₹550.0k (down 286% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 09
First quarter 2022 earnings released: ₹0.07 loss per share (vs ₹0.05 profit in 1Q 2021) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹1.94m (down 65% from 1Q 2021). Net loss: ₹754.0k (down 250% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 01
Third quarter 2021 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹2.0k (down 100% from 3Q 2020). Net loss: ₹1.13m (down ₹1.28m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 76% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Dec 07
New 90-day high: ₹3.33 The company is up 16% from its price of ₹2.88 on 08 September 2020. The Indian market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 5.0% over the same period. Valuation Update With 7 Day Price Move • Nov 20
Market bids up stock over the past week After last week's 17% share price gain to ₹2.17, the stock is trading at a trailing P/E ratio of 13.4x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 61x in the Biotechs industry in Asia. Total returns to shareholders over the past three years are 309%. Is New 90 Day High Low • Nov 11
New 90-day low: ₹1.73 The company is down 6.0% from its price of ₹1.84 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. Ankündigung • Jul 18
Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 31, 2020 Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results on Jul 31, 2020 